8:45am ET
Investing
The Biggest IPO of the Year Prompts Huge Insider Buy
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Companies
/Healthcare
Entrada Therapeutics Inc
$5.57
▲ $0.15 (+2.68%) today
Markets open · 3:42pm ET
TRDA at a Glance
Valuation
- Market cap
- $211.0M
Profitability
- Revenue (TTM)
- $4.7M
- EPS (TTM)
- $-3.96
Price
- 52-week range
- $5 – $16
- Street target
- $19.00
Earnings
- Next report
- Nov 5, 2026
Headquartered in Boston, MA Fiscal year ends December NASDAQ: TRDA entradatx.com
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on establishing a new class of genetic medicines that engage intracellular targets previously considered inaccessible. The company leverages proprietary endosomal escape vehicle (EEV) technology to develop oligonucleotide-based therapeutics. Its primary clinical focus is Duchenne muscular dystrophy (DMD), with lead programs ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51 targeting patients amenable to exon 44, 45, 50, and 51 skipping, respectively. Entrada has also partnered with Vertex Pharmaceuticals on VX-670 for the treatment of myotonic dystrophy type 1 (DM1). The company is expanding its pipeline into ocular diseases, including ENTR-801 for Usher syndrome type 2A, and is exploring metabolic disease applications. Entrada trades on Nasdaq under the ticker TRDA. Updated
Frequently Asked Questions
What does Entrada Therapeutics do?
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on establishing a new class of genetic medicines that engage intracellular targets previously considered inaccessible. The company leverages proprietary endosomal escape vehicle (EEV) technology to develop oligonucleotide-based therapeutics.
What is the TRDA stock price target?
The Wall Street consensus 12-month price target for TRDA is $19.00.